WA-T-MOBILE
20.9.2022 09:31:02 CEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) announced that ICE Cobotics, a global leader in cleaning technologies and equipment, has chosen T IoT as its exclusive IoT connectivity solution worldwide to help their customers more easily manage fleets of floor cleaning robots.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005555/en/
Floor cleaning and technology company picks T IoT to power i-SYNERGY fleet management software and strengthen its global subscription service (Photo: Business Wire)
As part of the long-term agreement, T IoT — a comprehensive solution for global IoT connectivity, platform management and support — will deliver cellular connectivity to more than 7,500 new and existing ICE Cobotics intelligent and autonomous cleaning units across the world. This includes their newest product, Cobi 18, a compact autonomous floor scrubber which is designed to clean 5,000 to 7,000 square feet per hour, starting at less than $20 a day.
ICE Cobotics chose T IoT to simplify the delivery and execution of IoT solutions on a global scale, which bolsters their mission to streamline processes for its customers. Less than a year ago, the company launched an industry first: an all-inclusive subscription service for floor cleaning machines, parts and maintenance, and performance and monitoring software. The service provides customers with a more reliable, affordable, and cost predictive solution, allowing them to use their capital to expand their business versus having it tied up in equipment ownership.
T IoT supports ICE Cobotics’ subscription model by delivering cleaning performance data and insights to customers in the retail, grocery, convenience, healthcare, higher education, and hospitality industries. Imagine a major retail corporation that has hundreds of robots in service. The cellular connectivity allows a customer’s maintenance and facilities team to view their Clean Score — goal-based cleaning performance data generated by ICE Cobotics’ i-SYNERGY fleet management software. This takes the guess work out of tracking cleaning efficacy, developing efficiencies, and confirming each location is clean. Previously, they would have had to visit each store to inspect if cleaning happened, which takes time and money.
Additionally, T IoT reinforces ICE Cobotics’ commitment to eliminate downtime by delivering over the air software and firmware updates to its customers, as well as mechanical telemetry data, from sensors and cameras in each machine, back to the company. This gives them the ability to monitor and analyze critical information like hours of use, routes, temperature, and battery life — so they can determine if certain components of a machine are operating within tolerance, if service is required and if a part is near its end of life — to prevent problems before they happen.
“T IoT is critical to the success of our cleaning machines and our all-inclusive subscription service,” said Mike DeBoer, President, ICE Cobotics U.S. “The data we receive from our autonomous scrubbers allows us to deliver cleaning performance insights and an enhanced clean to our customers at an affordable price.”
“This is what T IoT was designed for — helping enterprises solve global IoT challenges and deliver innovative solutions that make their customers want more,” said Callie Field, President, T-Mobile Business Group. “Like ICE Cobotics, T-Mobile and Deutsche Telekom share a passion for the pursuit of simple and we salute their ongoing mission to make things easier for their customers.”
To learn more about ICE Cobotics, visit www.us.icecobotics.com.
For more information about T IoT, visit www.t-mobile.com/business/solutions/iot/t-iot-global.
Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.
About T-Mobile
T-Mobile US, Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile and Metro by T-Mobile. For more information please visit: https://www.t-mobile.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom